Patent ID: 9012606
Filing Date: 2015-04-21
Classification: C07K

Abstract:
1. A fusion protein or peptide, comprising a physiologically active protein or peptide fused to alpha-1 antitrypsin variant having at least one mutated amino acid residue, whereby the physiologically active protein or peptide has an increased in vivo half-life by maintenance in a sustained circulation, and the alpha-1 antitrypsin variant has a reduced protease inhibitor activity, wherein the alpha-1 antitrypsin variant is selected from the group consisting of alpha-1 antitrypsin monovariant [α1AT(P357N)] set forth as SEQ ID NO:28, alpha-1 antitrypsin divariant [α1AT(P357N, S359T)] set forth as SEQ ID NO:29, alpha-1 antitrypsin divariant [α1AT(P357N, C232S)] set forth as SEQ ID NO:30, and alpha-1 antitrypsin trivariant α1AT(P357N, C232S, S359T) set forth as SEQ ID NO:31.